COVID-19 vaccine short-term adverse events in the real-life family practice in Krakow, Poland.
COVID-19 vaccine
family medicine
pragmatic study
primary care
vaccine adverse event
Journal
The European journal of general practice
ISSN: 1751-1402
Titre abrégé: Eur J Gen Pract
Pays: England
ID NLM: 9513566
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
8
6
2023
pubmed:
6
12
2022
entrez:
5
12
2022
Statut:
ppublish
Résumé
In manufacturers' trials, vaccination against COVID-19 proved to be safe and effective. The officially reported frequency of vaccine adverse events (VAEs) in Poland is lower than that declared by the manufacturers. The anti-vaccination activists questioned the trustworthiness of official data. The aim was to explore the real-life prevalence of VAEs in general practice settings and the factors that may influence it. In this pragmatic, mixed prospective and retrospective study, patients vaccinated against COVID-19 between May and October 2021 in three GP practices in Krakow, Poland, were enrolled. Their demographic (age, sex, level of education) and clinical data (weight and height, smoking status, history of allergies, COVID-19 and chronic diseases) were collected. Then, they were interviewed about VAEs they experienced. Out of 1530 patients invited to participate, 1051 (69%) agreed and were eligible for analyses. Only 8.8% did not report any VAE. Pain at the injection site was the most frequently reported reaction (800, 76.2%). The most prevalent systemic ones were excessive fatigue/lethargy (527, 50.6%), sleep/circadian rhythm disturbances (433, 41.6%) and headache (399, 38.3%). Fifty required medical assistance - 39 experienced presyncope (3.7%) and 11 loss of consciousness (1.1%). Only two others were hospitalised. Females, younger adults, those with higher education and with a history of COVID-19 reported systemic VAEs more frequently, while those who were older and obese were less likely to report local reactions. Although more than 90% of patients vaccinated against COVID-19 in general practice settings may experience VAEs, in short-term observation, the vast majority are localised and mild.
Sections du résumé
BACKGROUND
UNASSIGNED
In manufacturers' trials, vaccination against COVID-19 proved to be safe and effective. The officially reported frequency of vaccine adverse events (VAEs) in Poland is lower than that declared by the manufacturers. The anti-vaccination activists questioned the trustworthiness of official data.
OBJECTIVES
UNASSIGNED
The aim was to explore the real-life prevalence of VAEs in general practice settings and the factors that may influence it.
METHODS
UNASSIGNED
In this pragmatic, mixed prospective and retrospective study, patients vaccinated against COVID-19 between May and October 2021 in three GP practices in Krakow, Poland, were enrolled. Their demographic (age, sex, level of education) and clinical data (weight and height, smoking status, history of allergies, COVID-19 and chronic diseases) were collected. Then, they were interviewed about VAEs they experienced.
RESULTS
UNASSIGNED
Out of 1530 patients invited to participate, 1051 (69%) agreed and were eligible for analyses. Only 8.8% did not report any VAE. Pain at the injection site was the most frequently reported reaction (800, 76.2%). The most prevalent systemic ones were excessive fatigue/lethargy (527, 50.6%), sleep/circadian rhythm disturbances (433, 41.6%) and headache (399, 38.3%). Fifty required medical assistance - 39 experienced presyncope (3.7%) and 11 loss of consciousness (1.1%). Only two others were hospitalised. Females, younger adults, those with higher education and with a history of COVID-19 reported systemic VAEs more frequently, while those who were older and obese were less likely to report local reactions.
CONCLUSION
UNASSIGNED
Although more than 90% of patients vaccinated against COVID-19 in general practice settings may experience VAEs, in short-term observation, the vast majority are localised and mild.
Identifiants
pubmed: 36469611
doi: 10.1080/13814788.2022.2147500
pmc: PMC10249448
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2147500Références
Vaccines (Basel). 2021 Nov 15;9(11):
pubmed: 34835252
Vaccines (Basel). 2021 May 13;9(5):
pubmed: 34067955
Med J Aust. 2022 Aug 15;217(4):195-202
pubmed: 35781813
J Clin Med. 2021 Nov 16;10(22):
pubmed: 34830620
BMC Med. 2021 Jul 28;19(1):173
pubmed: 34315454
BMJ Open. 2022 Feb 14;12(2):e050062
pubmed: 35165107
Eur J Gen Pract. 2021 Dec;27(1):166-175
pubmed: 34282695
Infect Dis Poverty. 2021 Jul 05;10(1):94
pubmed: 34225791
Vaccine. 2021 Aug 23;39(36):5087-5090
pubmed: 34332800
JAMA Netw Open. 2021 Oct 1;4(10):e2131034
pubmed: 34698847
Eur J Gen Pract. 2020 Dec;26(1):182-188
pubmed: 33337939
Pilot Feasibility Stud. 2022 Jul 2;8(1):134
pubmed: 35780172
Vaccines (Basel). 2022 Mar 12;10(3):
pubmed: 35335066
Eur J Gen Pract. 2021 Dec;27(1):241-247
pubmed: 34431426
Front Public Health. 2021 Sep 22;9:719665
pubmed: 34631647
Eur J Gen Pract. 2021 Dec;27(1):176-183
pubmed: 34319199
Vaccine. 2022 Apr 20;40(18):2588-2603
pubmed: 35315324
BMC Infect Dis. 2022 Feb 23;22(1):179
pubmed: 35197017
Eur Rev Med Pharmacol Sci. 2021 Jun;25(12):4418-4421
pubmed: 34227078
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Int J Environ Res Public Health. 2022 Apr 27;19(9):
pubmed: 35564714